Literature DB >> 32373964

LncRNA AWPPH accelerates the progression of non-small cell lung cancer by sponging miRNA-204 to upregulate CDK6.

D Wu1, B-Y Qin, X-G Qi, L-L Hong, H-B Zhong, J-Y Huang.   

Abstract

OBJECTIVE: This study aims to uncover the function of long non-coding RNA (lncRNA) AWPPH in the progression of non-small cell lung cancer (NSCLC) and the potential mechanism. PATIENTS AND METHODS: AWPPH and microRNA (miRNA-204) levels in NSCLC tissues and adjacent normal tissues were detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Kaplan-Meier curves were introduced for assessing overall survival in NSCLC patients expressing high or low level of AWPPH. Potential correlation between expression levels of AWPPH and miRNA-204 in NSCLC tissues was analyzed by Spearman correlation test. Through Dual-Luciferase reporter gene assay, the interaction among AWPPH, miRNA-204, and CDK6 was identified. Potential impacts of AWPPH/miRNA-204/CDK6 regulatory loop on mediating proliferative, migratory, and invasive capacities of A549 cells were evaluated through cell counting kit-8 (CCK-8) and transwell assay.
RESULTS: Upregulated AWPPH and downregulated miRNA-204 were determined in NSCLC tissues. AWPPH level was negatively correlated to overall survival in NSCLC patients and miRNA-204 level in NSCLC tissues. Silence of AWPPH attenuated proliferative, migratory, and invasive capacities in A549 cells. MiRNA-204 was the downstream gene of AWPPH. Knockdown of miRNA-204 reversed the decreased viability, migratory, and invasive rates in A549 cells with AWPPH knockdown. In addition, CDK6 was the target gene of miRNA-204. Overexpression of miRNA-204 downregulated CDK6 level in A549 cells. The attenuated proliferative, migratory, and invasive capacities in A549 cells overexpressing miRNA-204 were reversed after CDK6 overexpression.
CONCLUSIONS: LncRNA AWPPH serves as the miRNA-204 sponge to upregulate CDK6 level, thus aggravating the progression of NSCLC.

Entities:  

Year:  2020        PMID: 32373964     DOI: 10.26355/eurrev_202004_21008

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

Review 1.  MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and Prognosis.

Authors:  Chenming Zhong; Zijun Xie; Ling-Hui Zeng; Chunhui Yuan; Shiwei Duan
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

Review 2.  Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders.

Authors:  Majid Ghasemian; Masoumeh Rajabibazl; Unes Sahebi; Samira Sadeghi; Reza Maleki; Veys Hashemnia; Reza Mirfakhraie
Journal:  Cancer Cell Int       Date:  2022-06-17       Impact factor: 6.429

3.  Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival.

Authors:  Rui Mu; Hongliang Liu; Sheng Luo; Edward F Patz; Carolyn Glass; Li Su; Mulong Du; David C Christiani; Lei Jin; Qingyi Wei
Journal:  Int J Cancer       Date:  2021-06-10       Impact factor: 7.396

4.  lncRNA FLVCR1‑AS1 drives colorectal cancer progression via modulation of the miR‑381/RAP2A axis.

Authors:  Yi Han; Xiaoyan Wang; Enqiang Mao; Boyong Shen; Liang Huang
Journal:  Mol Med Rep       Date:  2020-12-14       Impact factor: 2.952

5.  Reconstruction and analysis of the aberrant lncRNA-miRNA-mRNA network based on competitive endogenous RNA in adenoid cystic carcinoma of the salivary gland.

Authors:  Yu-Fang Tang; Wen-Jie Wu; Jian-Yun Zhang; Jie Zhang
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

6.  LncRNA AWPPH as a prognostic predictor in human cancers in Chinese population: evidence from meta-analysis.

Authors:  Yongfeng Li; Xinmiao Rui; Daobao Chen; Haojun Xuan; Hongjian Yang; Xuli Meng
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

7.  Long non-coding RNA MCM3AP antisense RNA 1 promotes non-small cell lung cancer progression through targeting microRNA-195-5p.

Authors:  Dijian Shen; Jianqiang Li; Kaiyi Tao; Youhua Jiang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.